+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy of syringomycin E in a murine model of vaginal candidiasis



Efficacy of syringomycin E in a murine model of vaginal candidiasis



Journal of Antibiotics 51(8): 743-749



Syringomycin E (SR-E), a new antifungal produced by the bacterium Pseudomonas syringae pv. syringae, was evaluated in a murine vaginal candidiasis model. In one study, mice were treated intravaginally b.i.d. for 4 days with drug carrier, SR-E 2% in either PEG-400 or PEG-ointment, or 1% clotrimazole as a positive control. Quantitative vaginal cultures were taken prior to treatment on day 1 and on days 5, 6, and 7. Both formulations showed a reduction of yeast colonization in the vaginas on day 5 (P< or =0.06 and P< or =0.03 for SR-E/PEG-400 and SR-E/PEG ointment, respectively) and SR-E/PEG ointment reduced the colonization on day 7 (P< or =0.06) when compared to carrier treated controls. In a second study, SR-E was formulated in Aquaphor at three higher concentrations of SR-E [3%, 6%, or 12% (w/v)]. SR-E showed dose-dependent efficacy. The 3% dose showed no effect while the 6% and 12% doses reduced the number of yeasts. The 12% dose showed a significant reduction on days 5 (P< or =0.01), 6 (P< or =0.06), and 7 (P< or =0.03) when compared with the drug carrier controls and on day 5 was more effective than clotrimazole (P< or =0.03). Clotrimazole did not significantly reduce the yeasts in the vagina until days 6 (P< or =0.01) and 7 (P< or =0.01) when compared to the drug carrier controls. No vaginal inflammatory response was evident by histological examination in uninfected animals treated with SR-E. No SR-E could be detected in plasma, kidney, or liver. SR-E (12%) was an effective treatment when compared to 1% clotrimazole.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 003123097

Download citation: RISBibTeXText

PMID: 9766466

DOI: 10.7164/antibiotics.51.743


Related references

Syringomycin E, a new antifungal, in a murine model of vaginal candidiasis Efficacy and local toxicity. Abstracts of the General Meeting of the American Society for Microbiology 97(0): 7, 1997

Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrobial Agents and ChemoTherapy 59(9): 5567-5573, 2016

Expression of MCP-1 and its receptor CCR2 in a murine model of experimental vaginal candidiasis. Zhonghua Pifuke Zazhi 39(8): 466-469, 2006

In vitro study on tetrandrine as a synergist to fluconazole in murine model of vaginal candidiasis. Chinese Journal of Zoonoses 23(5): 474-478, 483, 2007

Effects of antimicrobial peptide LL-37 expressed and purified from prokaryotes in the murine model of vaginal candidiasis. Zhonghua Fu Chan Ke Za Zhi 51(7): 530-534, 2017

Expression of stroma-derived factor 1 and its receptor CXCR4 in a murine model of vaginal candidiasis. Chinese Journal Of Dermatology: 8, 504-508, 2008

Utility of the oestrogen-dependent vaginal candidosis murine model in evaluating the efficacy of various therapies against vaginal Candida albicans infection. Mycoses 49(2): 104-108, 2006

Candida albicans inhibits dendritic cell surface molecule expression in a murine model of vaginal candidiasis. 2005

ERG2 and ERG24 Are Required for Normal Vacuolar Physiology as Well as Candida albicans Pathogenicity in a Murine Model of Disseminated but Not Vaginal Candidiasis. Eukaryotic Cell 14(10): 1006-1016, 2016

Local expression of vaginal Th1 and Th2 cytokines in murine vaginal candidiasis under different immunity conditions. Journal of Huazhong University of Science and Technology. Medical Sciences 28(4): 476-479, 2008

Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. Pathogens and Disease 75(6), 2017

Clinical efficacy of Pimafucin (natamycin) vaginal tablets in a ten-day course for vaginal candidiasis. New Zealand Medical Journal 91(661): 420-421, 1980

Efficacy of human salivary mucin MUC7-derived peptide and histatin 5 in a murine model of candidiasis. International Journal of Antimicrobial Agents 22(6): 594-600, 2003

Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. International Journal of Antimicrobial Agents 36(1): 33-36, 2010

Open studies of the efficacy, tolerance, systemic absorption and vaginal persistence following a single application of tioconazole ointment in the treatment of patients with vaginal candidiasis. Gynakologische Rundschau 23 Suppl 1: 12-19, 1983